Comparative Pharmacology
Head-to-head clinical analysis: FACTIVE versus NOROXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FACTIVE versus NOROXIN.
FACTIVE vs NOROXIN
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Gemifloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with DNA replication, transcription, repair, and recombination.
Noroxin (norfloxacin) is a fluoroquinolone antibacterial agent that inhibits DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes required for bacterial DNA replication, transcription, repair, and recombination.
Acute exacerbation of chronic bronchitis due to susceptible bacteriaCommunity-acquired pneumonia (mild to moderate) due to susceptible bacteria
Urinary tract infections (uncomplicated and complicated)ProstatitisSexually transmitted infections (e.g., gonorrhea)Traveler's diarrhea
400 mg orally once daily for 5 days for acute exacerbation of chronic bronchitis; 400 mg orally once daily for 7 days for community-acquired pneumonia; 400 mg orally once daily for 5 days for acute bacterial sinusitis.
400 mg orally twice daily for 3-14 days depending on indication.
None Documented
None Documented
12.5 hours (range 10-16 hours), supporting once-daily dosing.
Terminal elimination half-life is 6-7 hours in patients with normal renal function. Prolonged to 21-28 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Gemifloxacin is partially metabolized in the liver, primarily via glucuronidation and oxidation. The major metabolites are O-desmethyl gemifloxacin and gemifloxacin glucuronide. CYP450 involvement is minimal.
Norfloxacin is metabolized in the liver via N-dealkylation and glucuronide conjugation. It undergoes enterohepatic recirculation. Approximately 30% of an oral dose is excreted unchanged in the urine, with additional metabolites excreted renally.
Renal excretion of unchanged drug accounts for approximately 61% of the administered dose; fecal elimination accounts for about 35%, with a minor biliary component.
Renal excretion accounts for approximately 30% of the dose as unchanged drug. Biliary/fecal elimination is a major route, with about 60-70% recovered in feces as unchanged drug and metabolites.
~45% bound to serum proteins (primarily albumin).
30-40% bound to plasma proteins (primarily albumin).
3.0 L/kg, indicating extensive tissue penetration.
Volume of distribution is 2-3 L/kg, indicating extensive tissue penetration, including prostate, kidney, and urine.
75% oral bioavailability (tablet).
Oral bioavailability is 30-50% due to first-pass metabolism. Ophthalmic: Systemic bioavailability is minimal (<1%) after topical administration.
For CrCl 40-80 mL/min: no adjustment; CrCl <40 mL/min: not recommended; hemodialysis or peritoneal dialysis: not recommended.
CrCl 30-50 mL/min: 400 mg once daily; CrCl <30 mL/min: contraindicated.
No adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B); not studied in severe impairment (Child-Pugh C).
No adjustment required for mild-moderate hepatic impairment; severe impairment (Child-Pugh class C): caution, use lower dose if necessary.
Safety and efficacy not established in pediatric patients (<18 years); not recommended due to increased risk of adverse events.
Not recommended for children <18 years due to arthropathy risk.
No dose adjustment based on age alone; monitor renal function and adjust dose if CrCl <40 mL/min per renal adjustment.
Use with caution; consider renal function and reduce dose if CrCl <50 mL/min. Monitor for tendonitis and QT prolongation.
Fluoroquinolones, including gemifloxacin, have been associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is further increased in patients older than 60 years of age, in patients taking corticosteroids, and in patients with kidney, heart, or lung transplants.
Fluoroquinolones, including norfloxacin, are associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is further increased in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart, or lung transplants.
["Tendon effects (tendinitis, tendon rupture)","Exacerbation of myasthenia gravis","QT prolongation and arrhythmias","Peripheral neuropathy","Central nervous system effects including seizures and increased intracranial pressure","Photosensitivity/phototoxicity","Hypersensitivity reactions including anaphylaxis","Clostridioides difficile-associated diarrhea","Blood glucose disturbances","Renal impairment dose adjustment","Avoid use in patients with known aortic aneurysm or at risk"]
["Tendon damage (tendinitis and tendon rupture) – discontinue at first sign of pain or inflammation","Peripheral neuropathy – may occur rapidly; discontinue immediately","Central nervous system effects (e.g., dizziness, confusion, seizures) – use with caution in patients with CNS disorders","Exacerbation of myasthenia gravis – avoid use in patients with history of myasthenia gravis","Hypersensitivity reactions (including anaphylaxis) – discontinue and treat appropriately","QTc prolongation – use with caution in patients with risk factors for prolonged QTc","Photosensitivity/phototoxicity – avoid excessive sunlight or UV light","Clostridioides difficile-associated diarrhea – consider if diarrhea develops"]
["Hypersensitivity to gemifloxacin or any fluoroquinolone","History of tendinopathy or tendon rupture with fluoroquinolone use","Use in children under 18 years of age (except for specific infections)","Use in pregnant or nursing women unless benefit outweighs risk","Concurrent use with class IA or III antiarrhythmics (relative)"]
["Hypersensitivity to norfloxacin or any fluoroquinolone","History of tendon disorders related to fluoroquinolone use","Concurrent use with tizanidine (potent CYP1A2 inhibition leading to severe hypotension/sedation)","Pregnancy (FDA Category C; risk to fetus based on animal studies)","Lactation (excreted in breast milk; potential for serious adverse reactions in nursing infants)","Children and adolescents (<18 years of age) due to risk of arthropathy"]
Data Pending Review
Data Pending Review
Absorption is significantly reduced by concurrent intake of dairy products (milk, yogurt, cheese) or calcium-fortified juices. Also avoid antacids containing magnesium or aluminum, sucralfate, didanosine (chewable/buffered tablets), and multivitamins containing iron or zinc. Take gemifloxacin at least 2 hours before or 4 hours after these products.
Avoid dairy products (milk, yogurt) and calcium-fortified juices within 2 hours of dosing, as they can reduce absorption. Caffeine intake should be limited, as Noroxin may increase caffeine effects (nervousness, insomnia).
FDA Pregnancy Category C. First trimester: No adequate studies; potential risk based on animal studies (skeletal malformations). Second and third trimesters: Avoid due to risk of fetal cartilage damage and arthropathy (fluoroquinolone class effect). Use only if benefit outweighs risk.
NOROXIN (norfloxacin) is a fluoroquinolone antibiotic. It is contraindicated in pregnancy due to the risk of arthropathy in immature animals and potential fetal harm based on human data. First trimester: Avoid. Second and third trimesters: Avoid; associated with increased risk of aortic dissection and tendonitis. FDA Pregnancy Category C.
Excreted in breast milk; M/P ratio unknown. Avoid breastfeeding or use alternate drug due to potential arthropathy in infant. Consider discontinuing nursing or drug.
Norfloxacin is excreted in human breast milk. The milk-to-plasma ratio is approximately 0.9. Due to potential adverse effects on infant joint development and gastrointestinal flora, breastfeeding is not recommended during norfloxacin therapy. Consider alternative antibiotics or discontinue nursing.
No specific dose adjustment recommended in pregnancy. Pharmacokinetic changes may occur (e.g., increased Vd in pregnancy), but no data supporting dose change. Use lowest effective dose for shortest duration.
NOROXIN is contraindicated in pregnancy; therefore, no dose adjustments are recommended. If used inadvertently, pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, enhanced renal clearance) may require dose adjustments, but given the contraindication, alternative therapy should be sought.
Category C
Category C
Gemifloxacin (Factive) is a respiratory fluoroquinolone with enhanced activity against Streptococcus pneumoniae, including penicillin-resistant strains. It has a lower potential for phototoxicity compared to other fluoroquinolones but still caution is advised. Avoid use in patients with prolonged QT interval or those on antiarrhythmics. Adjust dose in renal impairment (CrCl <40 mL/min).
Noroxin (norfloxacin) is a fluoroquinolone antibiotic with limited systemic absorption; it is primarily used for uncomplicated urinary tract infections and prostatitis. Avoid coadministration with antacids, sucralfate, and iron or zinc supplements due to chelation. Use with caution in patients with known QT prolongation or those taking class IA/III antiarrhythmics. Noroxin is contraindicated in patients with a history of tendon disorders related to fluoroquinolones. Renal dose adjustment is required for CrCl <30 mL/min.
Take exactly as prescribed, without missing doses.Avoid taking with dairy products (milk, yogurt) or mineral supplements (calcium, iron, zinc) as they reduce absorption; separate by at least 2-4 hours.Drink plenty of fluids to prevent crystalluria.Report tendon pain or swelling immediately; avoid exercise if pain occurs.Avoid excessive sunlight or tanning beds; use sunscreen and protective clothing.May cause dizziness or lightheadedness; avoid driving until you know how you react.Complete the full course even if you feel better.
Take Noroxin on an empty stomach, at least 1 hour before or 2 hours after meals.Avoid antacids, iron supplements, zinc supplements, or sucralfate within 2 hours of taking Noroxin.Drink plenty of fluids to prevent crystalluria.Stop taking the medication and contact your doctor immediately if you experience tendon pain, swelling, or rupture, especially in the Achilles tendon.Report any signs of allergic reaction, such as rash, hives, or difficulty breathing.Noroxin may cause dizziness or lightheadedness; avoid driving or operating machinery until you know how it affects you.Complete the full course of therapy even if you feel better.Avoid excessive sun exposure and use sunscreen, as Noroxin can increase photosensitivity.